Colchicine for epidermolysis bullosa acquisita

Background: Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is difficult to treat. Recently one patient with severe EBA was described who responded dramatically to colchicine. Objective: Our purpose was to determine the efficacy of colchicine in the treatment of EBA. Methods: Four patients with severe EBA refractory to conventional therapy were treated with colchicine 0.6 to 1.5 mg a day for up to 4 years. Results: In all four patients the lessening of skin fragility and the decrease in spontaneous blister formation were dramatic; few side effects were noted. Conclusion: Colchicine should be considered in the treatment of EBA.